Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
KEYNOTE-355 demonstrated that adding pembrolizumab to first-line chemotherapy significantly prolongs overall survival in metastatic triple-negative breast cancer when tumors express PD-L1 with a combined positive score (CPS) of 10 or more. Patients with CPS <10 did not benefit. Pembrolizumab plus chemotherapy is the standard first-line immunotherapy regimen for CPS ≥10 metastatic TNBC.
Key Result 1: OS, CPS ≥10 — HR 0.73 (95% CI 0.55–0.95; p=0.0185) Key Result 2: OS, CPS ≥1 — HR 0.86 (95% CI 0.72–1.04; p=0.1125) — NOT significant
Safety Signal: Immune-mediated AEs occurred in 26.5% of the pembrolizumab arm (grade ≥3: 5.3%) vs 6.4% with placebo–chemotherapy (grade ≥3: 0%); 2 treatment-related deaths in the pembrolizumab arm.
✅ Patient Eligibility
Must Have:
- Centrally confirmed TNBC (ASCO-CAP guidelines)
- Locally recurrent inoperable or metastatic disease — first-line setting
- PD-L1 CPS ≥10 by 22C3 pharmDx assay (for approved indication)
- ECOG PS 0 or 1
- Measurable disease per RECIST v1.1
Cannot Have:
- Prior anti-PD-1/PD-L1/PD-L2 therapy
- Active autoimmune disease within 2 years
- Active CNS metastases
- History of noninfectious pneumonitis
💊 Dosing Quick Guide
Experimental Regimen
Pembrolizumab: 200 mg IV every 3 weeks Plus investigator's choice of:
- Nab-paclitaxel: 100 mg/m² IV days 1, 8, 15 q28d; OR
- Paclitaxel: 90 mg/m² IV days 1, 8, 15 q28d; OR
- Gemcitabine–carboplatin: Gemcitabine 1000 mg/m² + carboplatin AUC 2 IV days 1, 8 q21d
Duration: Up to 35 administrations of pembrolizumab (~2 years) or until progression
Control Regimen
Placebo IV every 3 weeks plus same chemotherapy options
Key Dose Modifications [2]
Per FDA prescribing information — not trial protocol - Withhold pembrolizumab for grade 2 pneumonitis, grade 2 colitis, grade ≥3 hepatitis/nephritis, or severe endocrinopathy; permanently discontinue for grade 3–4 pneumonitis or recurrent grade 2 - No dose reduction for pembrolizumab — withhold or permanently discontinue only - Monitor thyroid function at baseline and periodically; monitor liver function before each cycle
Mechanism: Pembrolizumab is an anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, restoring T-cell–mediated antitumor immunity [2].
⚠️ Safety Snapshot
| Grade ≥3 Toxicities | Pembro–Chemo (n=562) | Placebo–Chemo (n=281) |
|---|---|---|
| Neutropenia | 167 (29.7%) | 84 (29.9%) |
| Neutrophil count decreased | 98 (17.4%) | 57 (20.3%) |
| Anemia | 93 (16.5%) | 41 (14.6%) |
| ALT increased | 34 (6.0%) | 13 (4.6%) |
| Fatigue | 16 (2.8%) | 7 (2.5%) |
Grade specification: grade 3, 4, or 5 combined as reported in source.
⚠️ Immune-mediated AEs: Any grade 26.5% vs 6.4%; Grade ≥3: 5.3% vs 0%. No fatal immune-mediated AEs. Most common: hypothyroidism (15.8% vs 3.2%).
Key safety metrics:
- Treatment-related deaths: 2 (0.4%) vs 0
- Any TEAE: 554 (98.6%) vs 276 (98.2%)
- Grade ≥3 TEAE: 438 (77.9%) vs 207 (73.7%)
📊 Key Numbers
Median follow-up: 44.1 months
| Outcome (Population) | Pembro–Chemo | Placebo–Chemo | HR (95% CI) | p-value |
|---|---|---|---|---|
| OS (CPS ≥10) | 23.0 mo | 16.1 mo | 0.73 (0.55–0.95) | 0.0185 |
| OS (CPS ≥1) | 17.6 mo | 16.0 mo | 0.86 (0.72–1.04) | 0.1125 |
| OS (ITT) | 17.2 mo | 15.5 mo | 0.89 (0.76–1.05) | Not tested |
| PFS (CPS ≥10, updated) | 9.7 mo | 5.6 mo | 0.66 (0.50–0.88) | — |
| ORR (CPS ≥10, updated) | 52.7% | 40.8% | — | — |
| DOR (CPS ≥10, updated) | 12.8 mo | 7.3 mo | — | — |
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| KEYNOTE-355 | Pembro + chemo | 1L mTNBC, CPS ≥10 | OS | mOS 23.0 vs 16.1 mo; HR 0.73 | [1] |
| IMpassion130 | Atezo + nab-pac | 1L mTNBC, PD-L1 IC+ | OS (descriptive) | mOS 25.4 vs 17.9 mo; HR 0.67 | [4] |
| IMpassion131 | Atezo + paclitaxel | 1L mTNBC | PFS | Not significant; HR 0.82 | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
CPS ≥10: HR 0.71 (95% CI 0.54–0.93, unstratified) — clear survival benefit; drives the approval CPS 1–9: HR 1.09 (95% CI 0.85–1.40) — no benefit observed; possible harm signal CPS <1: HR 0.97 (95% CI 0.72–1.32) — no benefit CPS ≥20: HR 0.72 (95% CI 0.51–1.01) — benefit magnitude similar to CPS ≥10
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Approved: pembrolizumab + chemo for 1L mTNBC with CPS ≥10 [2] |
| EMA | Approved: pembrolizumab + chemo for 1L mTNBC with CPS ≥10 |
⚠️ Verify current regulatory status before prescribing.
NCCN: Category 1, preferred — pembrolizumab + chemo for 1L locally recurrent unresectable or metastatic TNBC with CPS ≥10 [3]
⚡ Grey Zones
- Patients with CPS 1–9 show no OS benefit (HR 1.09) — avoid adding pembrolizumab in this group despite PD-L1 positivity.
- OS by chemotherapy backbone (taxane vs gemcitabine–carboplatin) was not reported — unclear if benefit is consistent across all partners.
- Patients previously treated with neoadjuvant pembrolizumab (KEYNOTE-522) were excluded — retreatment benefit is unknown.
- Active CNS metastases were excluded — efficacy with treated/stable brain metastases is undefined.
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217-226. doi:10.1056/NEJMoa2202809
- Pembrolizumab (KEYTRUDA) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed March 2026.
- Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983-993. doi:10.1016/j.annonc.2021.05.355
- Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994-1004. doi:10.1016/j.annonc.2021.05.801